INTRODUCTION
Club cell protein (CC-16, also called CC10, SCGB1A1 or CCSP) is mainly secreted by the club cells along the tracheobronchial tree, diffuses passively into the bloodstream, and is finally rapidly eliminated by glomerular filtration 1 .
While the exact function of CC-16 is not known, it is suggested to be a protective mediator in the airway inflammatory process 2 and to have protective effects from oxidative stress on the respiratory tract 3, 4 . Serum CC-16 level is considered as a sensitive biomarker of airways epithelium integrity, transiently increasing following acute exposure to pulmonary irritants and decreasing after chronic exposures associated with an impairment or reduction of club cells. Overall the assay of CC-16 is a sensitive test to allow the detection of early damage to the respiratory epithelium 3 and because of its presumed relationship to inflammation, CC-16 has gained increasing interest as a biological marker in the study of chronic pulmonary diseases 5, 6 .
Asthma is a chronic inflammatory disorder of the airways characterised by increased airway responsiveness (AR) and associated with accelerate decline in lung function 7 . Although AR is a key characteristic of asthma 8 it may occur without asthma-like symptoms or previous diagnosis of asthma, which is called asymptomatic AR. 9 .
Findings on the association between CC-16 and asthma are conflicting. No association with asthma was observed in adults from a large cross-sectional study 10 , while a negative association was observed in participants with asthma in clinical studies 11, 12 . Only few large epidemiological studies evaluated the association between CC-16 level and lung function, providing evidence of a negative association 10, [13] [14] [15] . A negative association between serum CC-16 level and AR was described only in one cross-sectional study 14 , and no study evaluated the specific association with asymptomatic AR. Overall there is a lack of large epidemiological studies considering together the relations of serum CC-16 with asthma, lung function and AR. Our hypothesis is that serum level of CC-16 decreases in participants with asthma, impaired lung function and airway responsiveness. The aim of the present paper is to study the associations between serum CC-16 levels and asthma, impaired lung function and airway responsiveness in the French epidemiological study on the genetics and environment of asthma (EGEA) whom participants with or without asthma have been extensively characterized regarding respiratory phenotypes and lung function tests.
.
METHODS

Study population
EGEA is a cohort study based on an initial group of asthma cases, their first-degree relatives, and controls (first survey, n=2047) 16 . At the second survey 17 , detailed phenotyping was performed with lung function tests including methacholine challenge (see Figure 1 and the online supplemental population and protocol section). This analysis is based on participants who were adults at the second survey (≥ 16 years old, n=1570 adults) with available data on asthma, serum CC-16 level and who did not smoke 1 hour before the examination (N=1298).
Biological phenotypes
Serum CC-16 level was determined with latex immunoassay using a rabbit anti-CC-16
antibody (Dakopatts, Glostrup, Denmark) 18 and purified CC-16 protein as standards (see the online supplemental biological phenotypes section).
Serum creatinine was determined with standard traceable IDMS (isotope dilution mass spectrometry traceable) assay and its clearance was calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula 19 which depends on sex and age of participants.
Clinical phenotypes
Asthma and asthma related phenotypes
Current asthma referred to the report of asthma attacks or asthma treatment or asthma-like symptoms in the past 12 months 20 . Participants without current asthma and that never reported ever asthma were considered as controls. Based on five asthma symptoms over the past 12 months (wheezy breathlessness, woken up by chest tightness and by an attack of shortness of breath, attack of shortness of breath at rest and after exercise), the asthma symptom score was computed, as previously proposed 21, 22 .
Asthma control was assessed from survey questions and lung function, closely adapted from 
Pulmonary function
Pulmonary function test was performed using a standardized protocol with similar equipment across centres according to the ATS/ERS guidelines. FEV 1 and FVC percent predicted values were based on Stanojevic et al. reference equations 23 .
Airway responsiveness
Methacholine bronchial challenge test was performed in participants with no medical contraindication, unless baseline FEV 1 <80% predicted or FEV 1 post dilution was lower than 90% of the baseline FEV 1, following the same protocol the European Community Respiratory Health Survey (ECRHS) 24 . Airway hyper-responsiveness (AHR) was defined as a 20% fall in The degree of airway responsiveness was quantified by a transformed dose-response slope obtained regressing the percentage fall in FEV 1 on log10 methacholine dose 25 . Low values of slope correspond to high degree of bronchial responsiveness. We referred to participants without asthma but with airway responsiveness as "asymptomatic AR".
Ethics Statement
Ethical approval was obtained from the relevant institutional review board committees at Cochin Port-Royal Hospital and Necker-Enfants Malades Hospital, Paris. Written informed consent was signed by kin or guardians of the minors/children and all other adult participants.
Statistical analyses
Since CC-16 level strongly depends on glomerular filtration rate (eGFR) level ( and increased AR, the analyses were stratified by smoking status. All statistical analyses were performed using R version 2.14. and data on AR were available for 862 participants (see online result section for more details).
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RESULTS
Characteristics of the sample (
CC-16 Serum level
Overall, serum CC-16 geometric mean (GM) level was 12.4 µg/L, ranging from 2.2 to 70.6µg/L (Table 1) . CC-16 level was higher in men, increased with age, decreased in smokers and with pack-years smoked decreased with blood sampling time and was negatively correlated with eGFR ( Table 2 ). After adjustment for eGFR and blood sampling time, the negative associations with age and smoking were confirmed only in participants without asthma (beta=-0.04, p=0.06 and beta for trend=-0.08, p=0.006, respectively).
Associations between CC-16 and asthma
Univariate association between CC-16 level and current asthma (as reported in Table 1 In participants with asthma, no association was observed between CC-16 z-score and asthma control (p>0.10) or asthma score (p=0.08 for score≥2) and CC-16 levels did not vary with ICS 
Associations between CC-16 and lung function
In participants with asthma, no association was observed between CC-16 and lung function (table E1, online), and this result was confirmed also in non-ICS users (n=253, p=0.10).
In participants without asthma (Table 3) In participants with asthma no association was observed between CC-16 z-score and AR (table E1 online), and this result was confirmed also in non-ICS users.
In participants without asthma lower CC-16 level was associated with lower level in the doseresponse slope ( Figure 2a ) borderline higher risk of any AHR (PD20≤4mg) and high AHR (PD 20 ≤1mg) ( Table 3) . These results were confirmed also when FEV 1 % predicted was 
DISCUSSION
Using data from a large epidemiological study on asthma, we observed that reduced lung function and higher AR were associated with decreased CC-16 level only in participants without asthma. No significant association was observed between CC-16 level and current asthma.
The major assets of this study are the sample size, the standardization of the sample collection and the availability of clinical parameters. Definition of asthma case is precise 29 31 . However, with a cross-sectional approach, causal association between CC-16 and respiratory diseases could not be established.
We found no association between CC-16 level and asthma. Similarly, no association was observed with asthma in 859 participants to population-based multi-centre ECRHS 10 neither with asthma and bronchitis in 6531 men aged 67-77 year from a cross-sectional study 32 . To date, most evidence of an association between CC-16 and asthma comes from small (less than 100 participants) clinical studies, both in children 33, 34 and in adults 11, 12 . A possible explanation for this apparent discrepancy is that participants from clinical studies are more likely to have severe asthma than participants from population-based studies. Further, clinical samples are known to be vulnerable to selection bias that may compromise the generalizability of findings.
We found that FEV 1 and FEV 1 /FVC were associated with serum CC-16 level only in participants without asthma. Previously, a positive association between serum CC-16 and FEV 1 and FVC was observed by in 402 fire-fighters from a cross-sectional study 14 and with FEV 1 % predicted and FEV 1 /FVC ratio in adults from the general population in the ECHRS study 10 , after adjustment for the same large range of covariates, including blood sampling time. The association between lung function parameters and CC-16 found in our study is consistent with previous published results on an association between lung function and markers of inflammation, such as C-Reactive Protein 35 .
We observed a negative association between CC-16 level and AR in adults without asthma that was confirmed in participants without any asthmatic symptom and was also independent from bronchial calibre. 38 , that showed that the A38G polymorphism in the CC-16 gene was associated with both plasma CC-16 level and AR in 154 asymptomatic, young, healthy adults. In the EGEA study, we previously found that methacholine AHR was significantly related to asthma incidence in asymptomatic participants 9 . It could be postulated that asymptomatic AR might precede development of respiratory symptoms and asthma 36, 37 through mechanisms related with airway inflammation , damage to epithelium integrity and structural changes in the airway mucosa 39 that are associated with decreased CC-16 levels in the airway. Future longitudinal studies, especially on paediatric population, will be useful to evaluate the role of CC-16 as a prognostic marker for asthma.
The lack of association between CC-16 level and lung function or AR in asthmatic group could be partly explained by the complex mechanisms, including inflammation and oxidative stress that characterizes this disease, leading to less variability of CC-16 level in participants with asthma and less sensitivity to variation in AR. Further, the differential association between CC-16 and lung function and AR between participants without and with asthma support the evidence of heterogeneity of AR in asymptomatic and symptomatic participants 30 .
In conclusion, we observed that decreased CC-16 serum level were associated with asymptomatic airway responsiveness and impaired lung function, only in participants without asthma. Those results suggested that serum level of CC-16 may help detecting early damages of the lung epithelium integrity. Further longitudinal studies will help in understanding whether this information will be used for early detecting asthmatic trait. 
METHODS
Population and protocol
The EGEA combines a case-control and family study of adult and childhood asthma After overnight precipitation at 4ºC, the samples were centrifuged (2,000x g for 10 min) and CC-16 was determined in the supernatants. All samples were analyzed in duplicate at two different dilutions. The assay has a detection limit of 0.5 ng/ml and an average analytical recovery of 95%, with the intra-and interassay coefficients of variation ranging from 5 to 10% 3 . Serum creatinine was determined with standard traceable IDMS (isotope dilution mass spectrometry traceable) assay. 
RESULTS
Characteristics of the sample
Participants with asthma were younger and smoked less frequently than participants without asthma. Lung function parameters were lower and AHR (PD 20 ≤4mg) was more frequent in participants with asthma than in those without asthma.
Among participants who performed the methacholine test (N=862), 800 (514 with asthma and 286 without) had information about their reduction in FEV1 after a provocative dose of methacholine of 4mg (PD20<4mg 
